EN DE
Watch S&S Healthcare Holding Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

S&S Healthcare Holding Ltd. (4198) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of S&S Healthcare Holding Ltd. stock TWD 34.28, price TWD 45.70, that is 25.0% below the price, quality 43 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

SS S&S Healthcare Holding Ltd. logo Thin data Nov 10, 2026

S&S Healthcare Holding Ltd.

4198 · TWO
Expensive, weak quality

Our calculation puts a fair price 25% below what the stock costs today.

Low debt
Quality 43/100
Revenue last quarter 15% below a year ago.
Fair value 34.28 TWD · Overvalued
Weak Growth (revenue 3y −7.1 %/yr in TWD)
Loss-making · -23.5% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 12/100
Thin data
Estimate⚠ Small free float
Watch S&S Healthcare Holding Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

59.50 TWD 18.05 TWD Fair Value 34.28 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 18.05 TWD – 59.50 TWD · fair‑value band 25.71 TWD – 42.85 TWD · the 45.70 TWD price screens above the 34.28 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow S&S Healthcare Holding in your weekly email

Every Wednesday you see whether S&S Healthcare Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

S&S Healthcare Holding Ltd. focuses on the research and development, manufacture, and sales of medical imaging devices in Taiwan, the United States, Switzerland, and internationally.

Show moreShow less

It develops digital diagnostic X-ray systems; and researches, develops, and produces bone densitometry and body composition assessment products. The company was formerly known as Swissray Global Healthcare Holding Ltd. and changed its name to S&S Healthcare Holding Ltd. in August 2020.

S&S Healthcare Holding Ltd. was founded in 1988 and is headquartered in Taipei, Taiwan.

Stock analysis

S&S Healthcare Holding Ltd. (4198) currently trades at 45.70 TWD, while our estimate is 34.28 TWD, 25% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 25.71 TWD (bear) to 42.85 TWD (bull), the price of 45.70 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

S&S Healthcare Holding Ltd. reported revenue of 204M TWD in FY2025 versus 122M TWD in FY2021, a compound +13.7%/yr. Reported net income was −47.3M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $33.6M) Micro · P/S ratio 6.43 · EPS (TTM) −1.68 TWD · Net margin −23.5% · Return on equity −15.7% · Return on assets (EBIT) −19.4% (5-year average) · Operating margin −44.3% · Revenue (TTM) 172M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 9% below its 52-week high and 50% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −25%, 4198 screens richer than that median.

Fair Value

Bear 25.71 TWD Fair Value 34.28 TWD Bull 42.85 TWD
Price 45.70 TWD · Downside -25.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 66
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−131.3% (2020) → −23.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

4198 screens overvalued: fair value 25% below the price. Compare with Abbott Laboratories, →

Compare S&S Healthcare Holding Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −25.0% · Below median
Profitability
Return on assets −12.5% · Below median
Net margin (12 months) −23.5% · Below median
Operating margin (12 months) −44.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −14.5% · Bottom 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.86× · Priciest 25%
P/S (12 months) 6.39× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 4198
DexCom, Inc DXCM $79.92 $89.18 +12% vs 4198
Stryker Corporation SYK $324.29 $358.30 +10% vs 4198
STERIS plc STE $257.12 $279.53 +9% vs 4198
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 4198
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 4198
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 4198
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 4198
Medtronic plc MDT $101.59 $65.61 −35% vs 4198
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 4198

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

S&S Healthcare Holding Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "S&S Healthcare Holding Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/4198

Frequently asked questions

Is S&S Healthcare Holding Ltd. (4198) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 34.28 TWD versus a price of 45.70 TWD, about 25% lower (overvalued).
What is the fair value of 4198?
Our estimate for S&S Healthcare Holding Ltd. is 34.28 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 45.70 TWD.
What is the quality score of 4198?
S&S Healthcare Holding Ltd. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for S&S Healthcare Holding Ltd. (4198)?
Our calculated price target is the estimate of 34.28 TWD (as of Nov 10, 2026). Cautious scenario 25.71 TWD, optimistic scenario 42.85 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the S&S Healthcare Holding Ltd. stock forecast for 2026?
Our estimate puts fair value at 34.28 TWD, about 25% lower versus a price of 45.70 TWD (overvalued). Cautious scenario 25.71 TWD, optimistic scenario 42.85 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of S&S Healthcare Holding Ltd. (4198)?
S&S Healthcare Holding Ltd. reported trailing-twelve-month revenue of about 172M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of S&S Healthcare Holding Ltd. (4198)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For S&S Healthcare Holding Ltd. it is 34.28 TWD per share (as of Nov 10, 2026), against a price of 45.70 TWD.
Is S&S Healthcare Holding Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 4198 trades above its calculated fair value: price 45.70 TWD, fair value 34.28 TWD, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4198?
No. The price is what the market pays today (45.70 TWD); the fair value is what the company's own numbers justify (34.28 TWD). For S&S Healthcare Holding Ltd. the two are 11.42 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is S&S Healthcare Holding Ltd. worth?
The market values S&S Healthcare Holding Ltd. at about 1.1B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 45.70 TWD; our models calculate a fair value of 34.28 TWD per share.
What do the bullish and bearish scenarios say about 4198?
Our models span a range for S&S Healthcare Holding Ltd.: cautious scenario 25.71 TWD, base 34.28 TWD, optimistic 42.85 TWD per share (as of Nov 10, 2026, price 45.70 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of S&S Healthcare Holding Ltd. (4198)?
Balance-sheet figures for S&S Healthcare Holding Ltd. (as of Nov 10, 2026): return on equity −15.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 4198 from its 52-week high?
S&S Healthcare Holding Ltd. trades at 45.70 TWD, about 9% below its 52-week high of 49.95 TWD and 50% above the low of 30.50 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 34.28 TWD is for.
Which stocks are comparable to S&S Healthcare Holding Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is S&S Healthcare Holding Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 45.70 TWD, calculated fair value 34.28 TWD (−25%), Quality Score 43/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. S&S Healthcare Holding Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of S&S Healthcare Holding Ltd. (4198)?
The closing price on Nov 10, 2026 was 45.70 TWD. Our estimate is 34.28 TWD, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with S&S Healthcare Holding Ltd. right now?
The price sits above even our optimistic bull case (42.85 TWD). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of S&S Healthcare Holding Ltd.

How large is the market capitalisation of S&S Healthcare Holding Ltd. (4198)?
The market capitalisation of S&S Healthcare Holding Ltd. is 1.1B TWD (≈ $33.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of S&S Healthcare Holding Ltd. (4198)?
The price-to-sales ratio of S&S Healthcare Holding Ltd. is 6.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of S&S Healthcare Holding Ltd. (4198)?
Earnings per share at S&S Healthcare Holding Ltd. are −1.68 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of S&S Healthcare Holding Ltd. (4198)?
The net margin of S&S Healthcare Holding Ltd. is −23.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of S&S Healthcare Holding Ltd. (4198)?
The return on equity (ROE) of S&S Healthcare Holding Ltd. is −15.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of S&S Healthcare Holding Ltd. (4198)?
On an EBIT basis the return on assets of S&S Healthcare Holding Ltd. is −19.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of S&S Healthcare Holding Ltd. (4198)?
The operating margin of S&S Healthcare Holding Ltd. is −44.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at S&S Healthcare Holding Ltd. (4198)?
Revenue at S&S Healthcare Holding Ltd. is growing −14.5% versus a year earlier (3y avg −7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does S&S Healthcare Holding Ltd. (4198) generate?
The free cash flow of S&S Healthcare Holding Ltd. is −30.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does S&S Healthcare Holding Ltd. (4198) hold?
S&S Healthcare Holding Ltd. holds more cash than debt, 111M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch S&S Healthcare Holding Ltd. in the live analysis

One click puts S&S Healthcare Holding Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.